Risk Management


The FDA approved the DURYSTA implant in June 2020 for the treatment of open-angle glaucoma. DURYSTA.Recommendations and consent discusses the risk of endothelial cell loss (ECL), and provides a sample consent form to help educate patients about the risks and benefits. Both the recommendations and consent form address implanting more than one DURYSTA per eye.

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment

Six reasons OMIC is the best choice for ophthalmologists in America.

Best at defending claims.

An ophthalmologist pays nearly half a million dollars in premiums over the course of a career. Premium paid is directly related to a carrier’s claims experience. OMIC has a higher win rate taking tough cases to trial, full consent to settle (no hammer) clause, and access to the best experts. OMIC pays 25% less per claim than other carriers. As a result, OMIC has consistently maintained lower base rates than multispecialty carriers in the U.S.